BORIS FURMAN: Open Payments
NPI 1164695011 · MANALAPAN, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,900 in 115 payments from 26 companies in 2025. Trend: 2023 $1,839 · 2024 $1,757 · 2025 $1,900
Food & beverage: $1,884Speaker / faculty: $16
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 25 | $302 |
| Neurocrine BioSciences, Inc. | 10 | $201 |
| Teva Pharmaceuticals USA, Inc. | 15 | $179 |
| Lilly USA, LLC | 8 | $136 |
| Eisai Inc. | 8 | $135 |
| Averitas Pharma Inc. | 5 | $104 |
| PFIZER INC. | 5 | $91 |
| Lundbeck LLC | 5 | $90 |
| Novartis Pharmaceuticals Corporation | 3 | $73 |
| ARGENX US, INC. | 4 | $67 |
Products named: INGREZZA, AUSTEDO XR, UBRELVY, QULIPTA, Leqembi, AMYVID, QUTENZA, KESIMPTA.
Industry payments across NJ — which companies pay providers there.
